The University of Chicago Header Logo
Last Name


Michael H. Davidson to Rhabdomyolysis

This is a "connection" page, showing publications Michael H. Davidson has written about Rhabdomyolysis.

Connection Strength
  1. Benes LB, Bassi NS, Davidson MH. The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter? Prog Cardiovasc Dis. 2016 Sep - Oct; 59(2):145-152.
    View in: PubMed
    Score: 0.627
  2. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, Davidson MH. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol. 2013 Mar-Apr; 7(2):102-8.
    View in: PubMed
    Score: 0.472
  3. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19; 99(6A):3C-18C.
    View in: PubMed
    Score: 0.321
  4. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005 Jan 01; 95(1):120-2.
    View in: PubMed
    Score: 0.281
  5. Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf. 2004 Nov; 3(6):547-57.
    View in: PubMed
    Score: 0.278
  6. Davidson MH. Controversy surrounding the safety of cerivastatin. Expert Opin Drug Saf. 2002 Sep; 1(3):207-12.
    View in: PubMed
    Score: 0.239
  7. Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol. 2005 Nov 07; 96(9A):44K-49K; discussion 34K-35K.
    View in: PubMed
    Score: 0.074
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.